Concussion is a serious medical issue that impacts all facets of life. Emotional, physical and cognitive function can all be damaged temporarily or permanently. Concussion can cause serious pain and disability. The major sources of concussion in Canada are car and workplace accidents, slip and falls, sports accidents, and physical assault. Much of the testing for concussion remains objective and there is yet to be a single cheap test that can be easily administered to decisively diagnose concussion.
Mild concussion or traumatic brain injury (TBI) account for approximately 75% of all concussions.
A great deal of research funding is being invested in creating such a test. A new one has just been announced.
BrainBox has announced it is now testing a new diagnostic method for patients over the age of 18 that has received the FDA’s “breakthrough device” designation. BrainBox has indicated that:
The test combines the use of a biomarker measurement with computer neurological assessment.
It is initiating a pivotal trial of the device in support of the marketing approval in the US and internationally. They hope to have the study completed in about 20 months.
The test is intended for clinical lab settings and point of care (hospital and doctor’s office) and uses ‘in-vitro diagnostic serum measurement’ testing to detect specific biomarkers in the brain.
The intent is that the test results will produce a single score that will measure the severity of the concussive injury (TBI) and that the score will then guide the treatment of the injury. The test is AI enabled.
You can read all about BrainBox on their website.